|
|
ACADIA Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
|
|
|
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
|
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results
|
|
|
ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)
|
|
|
ACADIA Pharmaceuticals Announces Executive Leadership Change
|
|
|
ACADIA Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 6, 2018
|
|
|
ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and Science
|
|
|
ACADIA Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference on October 2, 2018
|
|
|
FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
|
|
|
Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s Disease Psychosis and Parkinson’s Disease Psychosis Published in The Journal of Prevention of Alzheimer’s Disease Suggest Potential for Treating Dementia-Related Psychosis
|
|
|
ACADIA Pharmaceuticals to Present at the Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018
|
|
|
ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results
|
|
|
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome
|
|
|
ACADIA Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 8, 2018
|
|
|
ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary
|
|
|
ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin)
|
|
|
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 20, 2018
|
|
|
ACADIA Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on June 13, 2018
|
|
|
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018
|
|
|
ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results
|
|
|
ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations
|
|
|
ACADIA Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 4, 2018
|
|
|
ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting
|
|
|
ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID
|
|
|
PMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinson’s Disease
|
|
|
ACADIA Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018
|
|
|
ACADIA Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference on March 13, 2018
|
|
|
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
|
|
|
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018
|
|
|
ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018
|
